Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.57+0.03 (+5.67%)
Close on Nov 18, 2026Market cap $223.77MP/E 2.6Yield –
Standard BioTools free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Standard BioTools's free cash flow for the twelve months ending Jun 30, 2026 was -$82.58M. For fiscal 2025 it was -$82.65M. The highest annual figure on record is -$5.04M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$82.65M | – |
| FY2024 | Dec 31, 2024 | -$151.81M | – |
| FY2023 | Dec 31, 2023 | -$46.12M | – |
| FY2022 | Dec 31, 2022 | -$93.20M | – |
| FY2021 | Dec 31, 2021 | -$57.33M | – |
| FY2020 | Dec 31, 2020 | -$28.13M | – |
| FY2019 | Dec 31, 2019 | -$37.74M | – |
| FY2018 | Dec 31, 2018 | -$25.57M | – |
| FY2017 | Dec 31, 2017 | -$25.66M | – |
| FY2016 | Dec 31, 2016 | -$44.20M | – |
| FY2015 | Dec 31, 2015 | -$38.72M | – |
| FY2014 | Dec 31, 2014 | -$30.03M | – |
| FY2013 | Dec 31, 2013 | -$5.04M | – |
| FY2012 | Dec 31, 2012 | -$19.86M | – |
| FY2011 | Dec 31, 2011 | -$19.22M | – |
| FY2010 | Dec 31, 2010 | -$13.05M | – |
| FY2009 | Dec 31, 2009 | -$20.31M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$47.17M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.67M | – |
| Q3 FY2025 | Sep 30, 2025 | -$23.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.56M | – |
| Q1 FY2025 | Mar 31, 2025 | -$35.34M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.44M | – |
| Q3 FY2024 | Sep 30, 2024 | -$30.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$40.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$63.26M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.93M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.46M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.47M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.84M | – |
| Q1 FY2021 | Mar 31, 2021 | -$19.82M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.44M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.94M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.43M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.33M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.02M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.43M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.40M | – |
| Q4 FY2018 | Dec 31, 2018 | -$658.00K | -236.2% |
| Q3 FY2018 | Sep 30, 2018 | -$4.26M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.40M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.25M | – |
| Q4 FY2017 | Dec 31, 2017 | $483.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.54M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.43M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.18M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.42M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.97M | – |
See a number that looks wrong?